SEC For	rm 4 FORM	4	UNITE	) STA	TES S	SECURITIE	ES AN	DE	хсна	NGE C	OMM	ISSION					
					Washington, D.C. 20549										OMB APPROVAL		
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).				Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940								SHIP	Estim	OMB Number: 323 Estimated average burden hours per response:		3235-0287 n 0.5	
1. Name and Address of Reporting Person* BUTITTA CYNTHIA M					2. Issuer Name <b>and</b> Ticker or Trading Symbol <u>Century Therapeutics, Inc.</u> [ IPSC ]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner					
(Last) (First) (Middle)					3. Date of Earliest Transaction (Month/Day/Year) 06/27/2023							Officer (give title Other (specify below) below)					
C/O CENTURY THERAPEUTICS, INC. 25 N 38TH STREET, 11TH FLOOR				4. If Ar	4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person					
(Street) PHILADELPHIA PA 19104												Form filed by More than One Reporting Person					
(City)	(City) (State) (Zip)				Rule 10b5-1(c) Transaction Indication   Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.												
		Tab	le I - Nor	n-Deriv	ative S	ecurities Ac	quired,	Disp	osed o	of, or Ber	eficial	ly Owned	ł				
1. Title of Security (Instr. 3) Date (Month/				action Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Yea	, Transaction I Code (Instr. 5			ities Acquire d Of (D) (Ins		Benefici	es ally Following	6. Own Form: I (D) or I (I) (Inst	Direct ndirect tr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
							Code	v	Amount	nount (A) or (D)		Transaction(s) (Instr. 3 and 4)					
		Т				curities Acq IIs, warrants						Owned		*			
1. Title of Derivative Security (Instr. 3)	Derivative Conversion Date Execution Security or Exercise (Month/Day/Year) if any		Date,	4. Transactic Code (Inst B)		6. Date Exercisable and Expiration Date (Month/Day/Year)			Amount of Securities		8. Price of Derivative Security (Instr. 5)			0. Dwnership Form: Direct (D) or Indirect I) (Instr. 4)	11. Natur of Indirec Beneficia Ownersh (Instr. 4)		

Stock Option (right to buy) Explanation of Responses:

\$3.19

1. The option vests on the earlier of (a) June 27, 2024, or (b) the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service through the applicable vesting date.

(D) Date Exercisable

(1)

Expiration Date

06/27/2024

Title

Common Stock

<u>/s/ Michael Diem, Attorney-</u>	in- oc/20/2022
<u>Fact</u>	06/29/2023
** Signature of Reporting Person	Date

or Number

of Shares

44,000

\$0.00

44,000

D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

06/27/2023

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

v

(A)

44,000

Code

A

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.